Home > Insider Trading > Filing (0001209191-19-053666)

Filing Details

Accession Number:: 0001209191-19-053666
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-10-18 19:58:08
Reporting Period:: 2019-10-16

Accepted Time:: 2019-10-18 19:58:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1706431	Vir Biotechnology Inc.	VIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569248	Kristina Burow	8755 W. Higgins Road, Suite 1025 Chicago IL 60631		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-16	11,666,665	$0.00	12,111,109	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-10-16	15,555,554	$0.00	15,555,554	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-10-16	1,000,000	$20.00	1,000,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2019-10-16	11,111,110	$0.00	11,111,110	$0.00
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2019-10-16	13,333,332	$0.00	13,333,332	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-10-16	555,555	$0.00	555,555	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-10-16	2,222,222	$0.00	2,222,222	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The Reporting Person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The Reporting Person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
These shares are directly held by GPLLC. Each of ARCH IX and ARCH Overage has a pecuniary interest in the shares held by GPLLC. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein, if any.